Drug Type CAR-T |
Synonyms CX 170, CX-170, CX170 |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators), CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Preclinical | India | 01 Aug 2025 | |
B-Cell Lymphoma | Preclinical | India | 01 Aug 2025 | |
Leukemia | Preclinical | United States | 07 May 2024 | |
Lymphoma | Preclinical | United States | 07 May 2024 |